Asthma is a common chronic respiratory disease in Singapore and it is the primary cause of chronic respiratory disease burden in childhood and early adulthood. Despite having one of the best healthcare systems in the world, our asthma mortality rates are several folds higher than other first world countries. Most asthma deaths are preventable. We illustrate a case of fatal asthma and highlight some learning points from this case.
2-3 times yearly and was given a course of prednisolone and bronchodilator nebulisations each time. Two months prior to his presentation to hospital, he was prescribed combination of ICS and Long-acting Beta agonist (LABA) by a GP but he was not taking it regularly, relying instead on a Salbutamol inhaler almost daily. Two days prior to admission, he had upper respiratory tract infection symptoms and was using his Salbutamol inhaler up to 4 times each day. He developed worsening breathlessness and chest tightness on the morning of his admission to hospital which was not relieved by his Salbutamol inhaler. His wife called for an ambulance after noticing that he was getting increasingly breathless. e ambulance paramedics initiated nebulisation of bronchodilators and supplemental oxygen but he went into cardiac arrest while still en-route to hospital. CPR was commenced immediately and he was intubated at the Emergency Department. He eventually had return of spontaneous circulation after 30 minutes of resuscitation and was transferred to the Medical Intensive Care Unit (MICU). Intravenous corticosteroids and regular bronchodilators were given.
On Day 2 of admission, the patient showed no brainstem re exes on neurological testing and an MRI brain showed changes consistent with hypoxic-ischaemic encephalopathy. e patient's condition continued to deteriorate and he eventually passed away one week later. Mr K's death could have been prevented by:
1. Early diagnosis, assessment of severity and appropriate treatment of asthma 2. Regular follow up for asthma and adjustment of treatment according to response 3. Early detection of worsening asthma control, self-management and use of a Written Asthma Action Plan (WAAP)
PRINCIPLES OF ASTHMA DIAGNOSIS AND MANAGEMENT (A) DIAGNOSIS
A diagnosis of asthma is made when the patient has a history of variable respiratory symptoms (e.g. wheeze, chest tightness and cough) and con rmed variable expiratory air ow limitation on lung function testing. It is important to note that air ow limitation may be seen in many other chronic respiratory diseases such as chronic obstructive pulmonary disease and bronchiectasis, but what distinguishes asthma from these conditions is the presence of variable expiratory air ow limitation. In asthmatics, the lung function may vary between completely normal and severely obstructed in the same patient. Similarly, patients with conditions such as eosinophilic
INTRODUCTION
Asthma is a chronic respiratory disease characterised by variable respiratory symptoms such as wheeze, breathlessness, chest tightness and cough. In Singapore, 4.9% of the population has asthma 1 and it is the primary cause of chronic respiratory disease burden in childhood and early adulthood 2 . Despite 81-95% of our population having access to asthma medications, our asthma mortality rate remains at a high of 16 per 100000, which is three times that of other developed nations such as the United States and New Zealand 1 . is prompted an audit of fatal and near-fatal (FA/NFA) asthma in 4 restructured hospitals in Singapore. Between 2011-2015, there were 340 patients which accounted for 384 FA/NFA events, 17.1% had no regular asthma follow-up, and 32.1% were not on inhaled corticosteroid (ICS) i.e. Step 1 of GINA 3 . Lack of prior treatment with ICS and follow-up were associated with greater risk of death and hypoxic encephalopathy.
e importance of a timely and accurate diagnosis of asthma, initiation of treatment with ICS and regular follow-up and assessment of asthma control is therefore a matter of paramount importance. Here, we present a patient with fatal asthma to illustrate some of the factors which could have prevented his demise.
CASE ILLUSTRATION
Mr K was a 44-year-old Chinese man who had a history of asthma since childhood. He was married with no children and worked as a sales manager. His asthma control was poor with symptoms 3-4 times a week. He doctor-hopped and saw di erent General Practitioners (GPs) for exacerbation about e pharmacological options for the long-term treatment of asthma fall into 3 main categories:
Controllers (Inhaled corticosteroids, ICS or Inhaled
Corticosteroids/Long-acting beta agonist, ICS/LABA combination inhaler): ese are used daily to prevent symptoms of asthma and reduce likelihood of exacerbations.
ey work by reducing airway in ammation and also help reduce bronchial hyperreactivity. ICS is the cornerstone of asthma therapy. 2. Relievers (Short-acting beta agonist, SABA): ese are used only as-needed for relief of worsening symptoms during an exacerbation. Ideally, the patient should not require any reliever therapy at all if their asthma is well-controlled. 3. Add-on therapies: ese may be considered when the patient has persistent symptoms and/or frequent exacerbations despite optimising their controller medications.
e use of regular ICS as the maintenance treatment to achieve control of asthma symptoms is recommended for most patients. Despite having "mild asthma", this group of patients still have airway in ammation 10 and they remain at risk of severe lifethreatening exacerbations 11 . e SYGMA 1 trial published this year compared the use of 1) regular budesonide-formoterol to 2) 'as-needed' budesonide-formoterol and 3) twice-daily placebo plus 'as-needed' SABA (current GINA Step 1) in patients with mild asthma 12 . Regular use of ICS provided the best degree of asthma control; ICS used 'as needed' was non-inferior to regular ICS in terms of preventing severe asthma exacerbations and most importantly, ICS used 'as needed' was superior to 'as needed' salbutamol for asthma control and prevention of exacerbations (64% lower rate of severe exacerbations). It is also important to realise that while short-acting bronchodilators provide fast and e ective symptom relief, they do not treat the underlying pathology -which is airway in ammation 13 -and regular use of short-acting bronchodilators is also associated with a higher risk of exacerbations 14 .
In summary, ICS is the most e ective treatment for asthma 15, 16 . Use of ICS in asthma: 1. Reduces mortality 2. Reduces exacerbations 3. Reduces healthcare costs 4. Improves lung function 5. Improves asthma symptoms and control 6. Reduces missed days at work or school Given the evidence presented above, we recommend the use of regular inhaled corticosteroids in all patients and to avoid monotherapy short-acting bronchodilators where possible as part of best clinical practice.
(D) REGULAR FOLLOW-UP FOR ASTHMA AND ADJUSTMENT OF TREATMENT ACCORDING TO RESPONSE
Asthma is a chronic disease and hence requires regular review by their healthcare practitioners. In control-based asthma bronchitis or chronic cough from upper airway cough syndrome may be wrongly labelled as having cough-variant asthma but these patients have normal spirometry and airway responsiveness 4 . Due to the presence of many asthma mimics (anxiety, vocal cord dysfunction, gastro-oesophageal re ux disease, etc), use of objective tests to con rm variable expiratory air ow limitation is highly recommended.
Fractioned exhaled nitric oxide (FeNO) is a non-invasive marker of eosinophilic airway in ammation. It has recently been shown to predict response to ICS in patients presenting with non-speci c respiratory symptoms (cough, breathlessness or wheeze for > 6 weeks) to primary care clinics 6 . e test is easy to perform and can be considered for clinical use especially in the primary care setting.
(B) ASSESSMENT OF ASTHMA SEVERITY
Asthma severity is assessed retrospectively during the healthcare visit based on the level of treatment needed in order to control asthma symptoms and prevent exacerbations 7, 8 . Asthma severity does not remain constant for a patient and frequent reassessment is needed.
(C) TREATMENT
e goal of asthma treatment is to achieve good symptom control and to minimize the risk of future exacerbations. E ective asthma management involves optimal pharmacological therapy and shared decision-making between the patient and his/her healthcare provider 9 . 
AND documented airflow limitation
The greater the variations, or the more occasions excess variation is seen, the more confident the diagnosis At least once during the diagnostic process when the FEV1 is low, confirm that FEV1/FVC is reduced Positive bronchodilator reversibility test 
Assess Control
At each follow-up visit, the healthcare practitioner should assess the patient's asthma control by taking history and using standardised tools such as the Asthma Control Test or Asthma Control Questionnaire. Patients who are current smokers should be advised to quit smoking, inhaler techniques should be checked at every visit and adherence to medications assessed.
Regular review is also important as there is often a mismatch between patients' perception of asthma control and actual outcomes (exacerbations, severe life-threatening asthma exacerbations etc.) 18 . In an online survey of 2467 patients with asthma from 8 Asian countries which included Singapore, 89% of patients felt that their asthma was well-controlled but in that same group of patients, 73% had experienced 1 or more exacerbations in the past year 19 . As patients tend to view good asthma control as being able to relieve symptoms from exacerbations instead of preventing them, healthcare practitioners are in the best position to educate patients on their condition, address the mismatch between patients' perception and reality of outcomes, and in uence their attitudes toward treatment.
Adjust Treatment
Depending on the assessment of asthma control during the visit, the patient's asthma medications are then adjusted accordingly. If a patient's asthma control remains poor despite optimisation of controller medications, rst con rm the diagnosis of asthma and exclude other conditions that may mimic asthma (e.g. congestive cardiac failure). Ensure that the patient has been adherent to usage of inhalers and that the inhaler technique is correct. Assess for the presence of modi able risk factors that may worsen asthma control and treat those accordingly. If all these have been thoroughly evaluated and asthma control still remains suboptimal, we suggest for an early referral to a Respiratory specialist for further evaluation.
(E) SELF MANAGEMENT AND USE OF WRITTEN ASTHMA ACTION PLANS
A written asthma action plan (WAAP) helps to guide patient self-management by providing written instructions on how patients can make small adjustments to their asthma medications based on changes in their level of symptoms. Figure  1 shows a sample of a WAAP. All asthma patients (or their caregivers) should be given one with clear instructions on how to use it.
CONCLUSION
Asthma is a chronic respiratory disease that is often under-recognised and under-treated. Untreated asthma can be fatal and even relatively asymptomatic patients can develop severe life-threatening asthma exacerbations. Morbidity and mortality from asthma are mostly preventable and we should aim to achieve good symptom control and to minimize the risk of future exacerbations for our patients. Most importantly, we need to develop a mindset of "Zero Tolerance Towards Asthma Deaths in Singapore." 
